Abstract
Uropathogenic extended-spectrum beta-lactamases-producing <em>Enterobacteriaceae</em> (ESBL-PE) remains a global cause of urinary tract infections (UTIs) among hospitalized patients as these enzymes hydrolysing 3<sup>rd</sup> generation cephalosporin's (3<sup>rd</sup> GC). Those bacteria may not respond to therapy and thus further limiting antimicrobial selections. This study aimed to detect uropathogenic <em>Enterobacteriaceae</em> producing ESBL genes and their antimicrobial resistance pattern.
Highlights
Enterobacteriaceae member commonly related to hospital acquired Urinary tract infection (UTI) infections, mainly catheter-related urinary tract infections (UTIs)
midstream urine (MSU): Mid-stream urine; GNB: Gram-negative bacteria; ESBL: Extended-spectrum β-lactamase; ESBL-producing Enterobacteriaceae (ESBL-PE): Extendedspectrum β-lactamase producing Enterobacteriaceae; 3rd GC: 3rd generation cephalosporin’s; NCCLS: National committee on clinical laboratory standards; CLSI: Clinical laboratory standard institute; UTI: Urinary tract infection; MHA: Mueller Hinton agar; MDR: Multidrug resistance; Escherichia coli: E.coli; Klebsiella pneumoniae: K. pnuemoniae; Enterobacter aerogenes: E. aerogenes; Species: spp Enterobacteriaceae member commonly related to hospital acquired UTI infections, mainly catheter-related UTIs
The present retrospective study is on the distribution of uropathogenic ESBL-EP genes and their antimicrobial resistance pattern in the Sudanese population who were admitted to the urology department at Academy Charity Teaching Hospital (ACTH)
Summary
Enterobacteriaceae member commonly related to hospital acquired UTI infections, mainly catheter-related UTIs. Enterobacteriaceae member commonly related to hospital acquired UTI infections, mainly catheter-related UTIs They are caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates with high recurrence rates of increasing antimicrobial resistance among those uropathogens [1,2]. With the wide use of extended-spectrum cephalosporin's antibiotic in the healthcare setting, used as first-line therapy for Enterobacteriaceae UTI, the major worry is the increased reports on the dissemination of HospitalAcquired UTI with ESBL-producing Enterobacteriaceae (ESBL-PE) that may limit available treatment options, as they contribute significantly to the rapid dissemination of resistant organisms and their genes [3,4]. The ESBLs are Accepted: June 28, 2021. Such data make information available and serve to understand the ESBLs genes distribution in 2008
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
